Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

18.2%

2 terminated/withdrawn out of 11 trials

Success Rate

81.8%

-4.7% vs industry average

Late-Stage Pipeline

55%

6 trials in Phase 3/4

Results Transparency

111%

10 of 9 completed trials have results

Key Signals

10 with results

Enrollment Performance

Analytics

Phase 3

5(45.5%)

Phase 2

5(45.5%)

Phase 4

1(9.1%)

11Total

Phase 3(5)

Phase 2(5)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (11)

Showing 11 of 11 trials

NCT05315479Phase 4Terminated

Safety and Pharmacokinetics of N1539 in Children 2 to <17 Years of Age Following Surgery

Role: lead

NCT05687253Phase 2Completed

Evaluation of Intubation Conditions Following BX1000 or Rocuronium in Subjects Undergoing Surgery

Role: lead

NCT02720692Phase 3Completed

Evaluation of N1539 Following Major Surgery

Role: lead

NCT03323385Phase 3Completed

Evaluation of Preoperative N1539 in Colorectal Surgery

Role: lead

NCT03434275Phase 3Completed

Evaluation of Preoperative N1539 in Total Knee Arthroplasty

Role: lead

NCT03348423Phase 2Completed

Evaluation of DEX-IN During Outpatient Procedures

Role: lead

NCT02678286Phase 3Completed

Evaluation of N1539 Following Abdominoplasty Surgery

Role: lead

NCT02675907Phase 3Completed

Evaluation of N1539 Following Bunionectomy Surgery

Role: lead

NCT02540265Phase 2Completed

Placebo-Controlled Evaluation of N1539 Following Bunionectomy Surgery

Role: lead

NCT02284243Phase 2Completed

Placebo-Controlled Evaluation of Intranasal Dexmedetomidine for Postoperative Analgesia Following Bunionectomy Surgery

Role: lead

NCT02169336Phase 2Terminated

Placebo-Controlled Evaluation of Intranasal Dexmedetomidine for Postoperative Analgesia Following Bunionectomy

Role: lead

All 11 trials loaded